ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.

ARS Pharmaceuticals Inc.

Ars Pharmaceuticals, Inc. (($SPRY)) has held its Q1 earnings call. Read on for the main highlights of the call. Ars Pharmaceuticals’ latest earning...

Ars Pharmaceuticals’ Earnings Call Highlights Growth and Risks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceut...

Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT), Neurogene (NGNE) and ARS Pharmaceuticals (SPRY)

ARS Pharmaceuticals ( ($SPRY) ) just unveiled an announcement. On May 15, 2026, ARS Pharmaceuticals reported first-quarter 2026 revenue of $22.7 mi...

ARS Pharmaceuticals Highlights Strong Neffy Growth and Global Expansion

ARS Pharmaceuticals ( ($SPRY) ) has shared an announcement. On May 12, 2026, ARS Pharmaceuticals’ board, acting on a recommendation from Chief Exec...

Market Cap	$888.65M	P/E Ratio	N/A
52W High	$18.90	52W Low	$6.66
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-26.0%	52W Position	22.4%
Overall Score	40	Value Score	50
Quality Score	34	Technical Score	36

EPS Current Est	$-1.75	EPS Next Est	$-0.82
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SPRY	$9.40	+10.59%	2.61M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SPRY	$9.40	+10.6%	2.61M
3
4
5
6

SPRY

SPRY

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get ARS Pharmaceuticals Inc. Data in Excel

Get ARS Pharmaceuticals Inc. Data in Excel